Personalized mRNA Cancer Therapy Clears Phase 3 Hurdle, Meeting Both Post-Surgery Melanoma Recurrence Endpoints

Even after melanoma has been completely removed, residual cancer cells hidden in the body may still seize an opportunity to cause recurrence. Moderna and Merck have now announced that intismeran autogene, an mRNA therapy tailored to each patient’s tumor mutations, combined with the immunotherapy Keytruda, improved both recurrence-free survival and distant metastasis-free survival in a large Phase 3 trial, enabling a personalized cancer vaccine to clear a major late-stage clinical research hurdle for the first time.

INTerpath-001 is a global, randomized, double-blind Phase 3 trial that enrolled 1,137 patients whose stage IIB to IV cutaneous melanoma had been completely resected but who remained at high risk of recurrence. Participants were assigned in a 2-to-1 ratio, with approximately two-thirds receiving intismeran plus Keytruda and the remainder receiving Keytruda alone; the latter is currently an important option for adjuvant treatment after melanoma surgery.

The two companies said a prespecified interim analysis showed that the combination therapy achieved statistically significant improvements judged to be clinically meaningful in both the primary endpoint of recurrence-free survival and the key secondary endpoint of distant metastasis-free survival. This means that recurrence, death, or the spread of cancer to distant organs occurred later during follow-up. However, the announcement did not provide hazard ratios, actual survival rates, or follow-up duration, so the magnitude of the benefit cannot yet be determined.

intismeran is not a traditional vaccine intended to prevent cancer in healthy people. Researchers first analyze a patient’s resected tumor to identify mutations unique to the cancer cells, then produce mRNA carrying instructions for multiple neoantigens in an effort to teach T cells to recognize the patient’s own cancer cells. Keytruda blocks the PD-1 immune brake, giving the activated immune response a better opportunity to work. The strategy centers not only on the mRNA delivery platform but also on the complete process of tumor sequencing, antigen selection, and manufacturing a drug for each individual patient.

On safety, the companies said only that the results were consistent with those from earlier studies of the combination and that no new safety signals were identified. They have not yet disclosed serious adverse events, discontinuation rates, or specific differences between the two groups. The trial will also continue to track secondary endpoints including overall survival; until the mortality data mature, it cannot currently be inferred that delaying recurrence will necessarily translate into longer life.

Background

An earlier Phase 2 trial showed that intismeran combined with Keytruda, compared with Keytruda alone, reduced the risk of recurrence or death by 49% and the risk of distant metastasis or death by 59%. However, the Phase 2 study enrolled only 157 people, and those figures cannot be applied to the current Phase 3 results. Whether the new trial reproduces benefits of the same magnitude will remain unknown until the complete data are available.

Moderna and Merck plan to present detailed results at an international medical conference and discuss filing plans with regulators. If the complete analysis supports this preliminary conclusion, the significance would extend beyond melanoma: it would provide the first positive Phase 3 evidence for a treatment model manufactured according to tumor mutations and then combined with an immune checkpoint inhibitor. The true tests will include overall survival, long-term safety, the speed of personalized manufacturing, and clinical accessibility.